Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial

被引:18
|
作者
Gontijo-Amaral, Clesio [1 ]
Guimaraes, Elizabet V. [1 ]
Camargos, Paulo [1 ,2 ]
机构
[1] Fed Univ Minas Gerais UFMG, Fac Med, Dept Pediat, Diagnost Support Act & Res Ctr NUPAD, Belo Horizonte, MG, Brazil
[2] Univ Fed Sao Joao del Rei, Postgrad Program Hlth Sci, Hlth Sci Ctr, Divinopolis, Brazil
来源
关键词
RESPIRATORY MUSCLE STRENGTH; ASTHMATIC-CHILDREN; DIETARY MAGNESIUM; LONG-TERM; HYPOMAGNESEMIA; INFLAMMATION; METAANALYSIS; PRESSURES; PANCREAS; DISEASE;
D O I
10.3945/ajcn.112.034207
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Magnesium is one of the most important minerals in the body. Although some studies reported that patients with cystic fibrosis (CF) lack magnesium, no international study has assessed the importance of oral magnesium supplementation in CF patients. Objective: We prospectively investigated the long-term effect of oral magnesium supplementation on respiratory muscle strength by using manuvacuometry and the Shwachman-Kulczycki (SK) score among children and adolescents with CF. Design: This double-blind, randomized, placebo-controlled crossover study included 44 CF patients (aged 7-19 y; 20 males) who were randomly assigned to receive magnesium (n = 22; 300 mg/d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials. All patients were undergoing conventional treatment of CF. The experimental protocol included clinical evaluation, assessment of urinary concentration of magnesium, and manuvacuometric measurements [maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)]. MIP was the primary outcome. Results: Urinary magnesium increased after the administration of magnesium (change: 36.38 mg/d after magnesium compared with 0.72 mg/d after placebo; P < 0.001). Moreover, MIP and MEP significantly improved only after magnesium administration (change in MIP: 11% predicted after magnesium compared with 0.5% predicted after placebo; change in MEP: 11.9% predicted after magnesium compared with 0.8% predicted after placebo; P < 0.001 for both). Magnesium administration had a beneficial effect on clinical variables assessed by the SK score (change: 4.48 points after magnesium compared with -1.30 points after placebo; P < 0.001). Conclusion: Oral magnesium supplementation helped improve both the SK score and respiratory muscle strength in pediatric patients with CF. This trial was registered at www.ufmg.br.bioetica/coep as CAAEO 559.0.203.000-07. Am J Clin Nun 2012;96:50-6.
引用
下载
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [21] Modafinil Improves Real Driving Performance in Patients with Hypersomnia: A Randomized Double-Blind Placebo-Controlled Crossover Clinical Trial
    Philip, Pierre
    Chaufton, Cyril
    Taillard, Jacques
    Capelli, Aurore
    Coste, Olivier
    Leger, Damien
    Moore, Nicholas
    Sagaspe, Patricia
    SLEEP, 2014, 37 (03) : 483 - 487
  • [22] Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial
    Ullah, Hammad
    Di Minno, Alessandro
    Piccinocchi, Roberto
    Buccato, Daniele Giuseppe
    De Lellis, Lorenza Francesca
    Baldi, Alessandra
    El-Seedi, Hesham R.
    Khalifa, Shaden A. M.
    Piccinocchi, Gaetano
    Xiao, Xiang
    Sacchi, Roberto
    Daglia, Maria
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 169
  • [23] A randomized, double-blind, placebo-controlled crossover study on oral ATP administration
    Coolen, Erik
    Arts, Ilja
    Bours, Martijn
    Huyghebaert, Nathalie
    Cohen, Stuart Martien
    Bast, Aalt
    Dagnelie, Pieter
    PURINERGIC SIGNALLING, 2008, 4 : S196 - S197
  • [24] Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial
    Philip, P.
    Chaufton, C.
    Taillard, J.
    Capelli, A.
    Coste, O.
    Leger, D.
    Moore, N.
    Sagaspe, P.
    JOURNAL OF SLEEP RESEARCH, 2014, 23 : 33 - 33
  • [25] A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus
    Chainani-Wu, N.
    Silverman, S., Jr.
    Reingold, A.
    Bostrom, A.
    Mc Culloch, C.
    Lozada-Nur, F.
    Weintraub, J.
    PHYTOMEDICINE, 2007, 14 (7-8) : 437 - 446
  • [26] Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial
    Weiner, M
    Stein, A
    Cash, S
    de Leoz, J
    Fine, JD
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (03) : 613 - 614
  • [27] Urinary magnesium excretion in asthmatic children receiving magnesium supplementation:: a randomized, placebo-controlled, double-blind study
    Bede, O
    Surányi, A
    Pintér, K
    Szlávik, M
    Gyurkovits, K
    MAGNESIUM RESEARCH, 2003, 16 (04) : 262 - 270
  • [28] Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial
    Tangpricha, Vin
    Lukemire, Joshua
    Chen, Yuqing
    Binongo, Jose Nilo G.
    Judd, Suzanne E.
    Michalski, Ellen S.
    Lee, Moon J.
    Walker, Seth
    Ziegler, Thomas R.
    Tirouvanziam, Rabin
    Zughaier, Susu M.
    Chesdachai, Supavit
    Hermes, Wendy A.
    Chmiel, James F.
    Grossmann, Ruth E.
    Gaggar, Amit
    Joseph, Patricia M.
    Alvarez, Jessica A.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2019, 109 (03): : 544 - 553
  • [29] Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial
    Forrester, Doug L.
    Knox, Alan J.
    Smyth, Alan R.
    Barr, Helen L.
    Simms, Rebecca
    Pacey, Sarah J.
    Pavord, Ian D.
    Honeybourne, David
    Dewar, Jane
    Clayton, Andy
    Fogarty, Andrew W.
    PEDIATRIC PULMONOLOGY, 2016, 51 (03) : 253 - 257
  • [30] Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia
    Thompson, K. P.
    Sykes, J.
    Chandakkar, P.
    Marambaud, P.
    Vozoris, N. T.
    Marchuk, D. A.
    Faughnan, M. E.
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)